June 5, 2024 Sophia Vida
Breaking News

Setting the Stage for Success: PRISM MarketView Highlights Soligenix’s Promising HyBryte™ Replication Trial

NEW YORK, N.Y., June 5, 2024 – PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting Soligenix Inc’s (Nasdaq: SNGX) key achievements and pathway to regulatory success through its lead product candidate, HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma, a rare and chronic … Continue reading “Setting the Stage for Success: PRISM MarketView Highlights Soligenix’s Promising HyBryte™ Replication Trial”